Infinium Pharmachem Ltd Directors Report

Dear Members,

Your directors have pleasure in presenting the 22nd Boards Report of Infinium Pharmachem Limited (the Company) for the year ended on March 31, 2026 (period under review).

1. FINANCIAL HIGHLIGHTS AND PERFORMANCE:

Particulars	Standalone Basis For the year ended March 31, 2026	Standalone Basis For the year ended March 31, 2025	Consolidated Basis For the year ended March 31, 2026	Consolidated Basis For the year ended March 31, 2025
Gross Total Income / Gross Receipt	15785.66	13904.58	19176.96	15782.53
Profit Before Interest & Depreciation	1837.92	1728.44	2370.32	1853.62
Less: Interest & Financial Cost	229.17	269.57	280.20	367.19
Profit Before Depreciation & Taxation	1608.75	1458.87	2090.12	1486.43
Less: Depreciation	257.28	298.31	306.09	329.45
Profit After Depreciation Before Tax	1351.47	1160.56	1784.03	1156.98
Less: Current Income tax	355.14	309.87	375.61	370.39
Previous Year Tax Assets (-) / Liability	(2.87)	15.44	(2.26)	15.53
Deferred Tax Assets (-) / Liability	(2.55)	(11.63)	(9.24)	(13.23)
Net Profit After Tax	1001.75	846.88	1419.92	784.29
APPROPRIATIONS	-	-	-	-
Proposed Dividend	0	0	0	0
Tax on Proposed Dividend	0	0	0	0
Transfer to General Reserve	0	0	0	0
Balance Carried Forward to Next Year	1001.75	846.88	1419.92	784.29

2. STATE OF THE COMPANYS AFFAIRS & FUTURE PROSPECTS:

The Company is engaged in the business of manufacturing and supply of pharmaceutical formulations, healthcare products, veterinary products, and allied medical preparations in India and abroad, either directly or through its subsidiaries/business associates.

Highlights of Standalone Performance:

During the year under review, the Company has reported Net Revenue from Operations of Rs. 1564464.40 thousand as compared to Rs. 1369163.82 thousand in FY 2024-25. The Company has reported Earnings After Tax to Rs. 100174.56 thousand in FY 2025-26 from Rs. 84688.21 thousand in FY 2024-25. The Company has continued to demonstrate sustained growth, and the Board of Directors remains confident that its performance will further strengthen in the years ahead through its ongoing strategic initiatives and operational excellence.

Highlights of Consolidated Performance:

During the year under review, the Company has reported consolidated Net Revenue from Operations of Rs. 1896316.64 thousand as compared to Rs. 1557092.32 thousand in FY 2024-25. The Company has reported Earnings After Tax to Rs. 141992.24 thousand in FY 2025-26 from Rs. 78429.45 thousand in FY 2024-25. The Group has continued to exhibit a strong and resilient performance, reflecting the sustained growth and operational excellence demonstrated by the Company and its subsidiaries. The Directors remain confident that, supported by the collective strengths, strategic initiatives, and continued efforts of all entities within the Group, the Group is well positioned to further enhance its performance and achieve sustainable growth in the coming years.

1 Status on expansion and workings of the Company: We are pleased to inform that the Company has commissioned its contrast media raw materials manufacturing facility at Plot No. 1, GIDC Sojitra, District Anand, Gujarat on 16th January, 2026. The commissioning represents an important step in the Companys forward integration strategy, enabling Infinium Pharmachem Limited to enter the contrast media value chain. Leveraging its established expertise in iodine-based chemistry, the Company aims to address higher-value opportunities across a range of end-use applications. The contrast media segment is expected to be a key growth driver. Over the next 3 years, the Company is targeting annual revenue of approximately Rs. 100 crore from this segment, with an anticipated EBITDA margin of around 30%. This will increase the blended EBITDA margin to around 20%. This expansion marks a step-up into value-added contrast media-related offerings serving pharmaceutical, diagnostic imaging, and healthcare applications, aligned with the Companys long-term growth objectives.

Status on expansion and workings of the Company:

We are pleased to inform that the Company has commissioned its contrast media raw materials manufacturing facility at Plot No. 1, GIDC Sojitra, District Anand, Gujarat on 16th January, 2026.

The commissioning represents an important step in the Companys forward integration strategy, enabling Infinium Pharmachem Limited to enter the contrast media value chain. Leveraging its established expertise in iodine-based chemistry, the Company aims to address higher-value opportunities across a range of end-use applications.

The contrast media segment is expected to be a key growth driver. Over the next 3 years, the Company is targeting annual revenue of approximately Rs. 100 crore from this segment, with an anticipated EBITDA margin of around 30%. This will increase the blended EBITDA margin to around 20%.

This expansion marks a step-up into value-added contrast media-related offerings serving pharmaceutical, diagnostic imaging, and healthcare applications, aligned with the Companys long-term growth objectives.

3. TRANSFER TO RESERVES:

During the year under review, the Company has not transferred any amount to reserves.

4. DIVIDEND:

The Directors have not recommended any Dividend during the year under review.

5. CHANGE IN THE NATURE OF BUSINESS:

There has been no change in the nature of Business of the Company during the year under review.

6. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR:

There have been no material changes and commitments, which affect the financial position of the company which have occurred between the end of the financial year to which the financial statements relate and the date of this Report.

However, the Gujarat Pollution Control Board (GPCB) has issued direction to the Company under Section 33 (A) of the Water (Prevention and Control of Pollution) Act, 1974 on April 13, 2026 to close the operations at its plant located at Plot 38-39, GIDC Sojitra, Anand 387240. However, the said direction was revoked by the GPCB vide their letter dated May 20, 2026 and the business operations were resumed on May 20, 2026.

There was no adverse impact on the financial position of the Company as it had sufficient finished stock to meet the demand during that period.

7. SHARE CAPITAL:

The Authorized Share Capital of the Company as on March 31, 2026 is Rs. 25,00,00,000/- (Rupees Twenty-Five Crores Only) divided into 2,50,00,000 (Two Crore and Fifty Lakh) Equity Shares having Face Value of Rs. 10/- (Rupees Ten Only) each.

The Paid-up Equity Share Capital of the Company as on March 31, 2026 is Rs. 15,58,31,200 /- (Rupees Fifteen Crores Fifty-Eight Lakhs Thirty-One Thousand Two Hundred Only) consisting of 1,55,83,120 (One Crore Fifty-Five Lakhs Eighty-Three Thousand One Hundred and Twenty Only) Equity Shares having Face Value of Rs. 10/- (Rupees Ten Only) each.

8. SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE:

The Company has following subsidiaries, associates and Joint ventures:

Sr. No.	Name	Subsidiary/Associate/Joint Venture	Holding	Main object
1.	Shanghai Taijilin Industrial Co. Ltd	Foreign Joint Venture Subsidiary (JV Company)	51%	International Trade of Chemicals, Pharmaceuticals and other products mainly between but not limited to India and China.

Sr. No.	Name	Subsidiary/Associate/Joint Venture	Holding	Main object
2.	Infinium Green Energy Private Limited	Subsidiary Company	51%	Manufacture, production, sale, purchase, import, export, development, storage, accumulation, or otherwise dealing in Bio Coal, Bio Gas, Bio Energy, agro waste briquettes, white coal and Biomass Briquettes and other products related to renewable energy and non-conventional sources of energy from agricultural Cellulosic, waste including hemicellulose waste, other waste, recycling material or from any sources of energy and related products
3.	Infinium Healthcare Private Limited	Subsidiary Company	51%	To carry on the business, in India or abroad, of manufacturing, trading, importing, exporting, distributing, and marketing all types of pharmaceutical products, including formulations, bulk drugs, medicines (allopathic, ayurvedic, homeopathic, etc.), healthcare and wellness products, cosmetics, personal care items, medical consumables, and nutritional supplements\u2014for human and veterinary use.
4.	IBL Elements INC, USA	Associate Concern *	50%	To extract iodine from salt water, ensuring the purity level of brine water, and purification of waste water during mineral extraction.

*However Infinium Pharmachem Limited does not directly hold any share in IBL Elements. The share in IBL Elements are held by its subsidiary, Infinium Healthcare Private Limited.

Details of the said Subsidiary Company and Joint Venture are mentioned in Annexure A (Form AOC-1) annexed to this report.

9. STATUTORY AUDITOR & AUDIT REPORT:

Ashok Rajpara & Co., (FRN 153195W) has been appointed as the Statutory Auditor of the Company from the Financial Year 2022-23 to 2026-27 i.e. for the period of 5 years.

The Auditors Report does not contain any qualification. Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments.

10. SECRETARIAL AUDITOR:

The Board had appointed M/s. RTBR & Associates, Ahmedabad a firm of Company Secretaries in Practice, to carry out Secretarial Audit under the provisions of Section 204 of the Companies Act, 2013 for the Financial Year 2026-27.

The Secretarial Audit Report for the year under review is annexed to this report as Annexure B.

11. REPORTING OF FRAUD, COMMENTS BY BOARD ON EVERY QUALIFICATION, RESERVATION, ADVERSE REMARK OR DISCLAIMER:

During the period under review, no frauds were reported by the auditors of the Company under section 143(12) of the Companies Act, 2013. Therefore, the Board has not commented on the same.

12. DETAILS OF DIRECTORS OR KEY MANAGERIAL PERSONNEL: The Board of Directors of the Company is duly constituted in accordance with the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as applicable. During the year under review, there was no change in the directors during the year. However, the Company has appointed Mr. Kunj Anjaykumar Desai as a Company Secretary and Chief Financial Officer consequent to promotion of Mr. Nilesh Patel to the post of Executive Director- Finance, (Non-Board) with effect from 01st April, 2026 pursuant to the approval of the Board of Directors at its meeting held on 13th March, 2026, and has complied with all the applicable provisions of the Companies Act, 2013 read with rules made thereunder and SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and other applicable laws in this regard. As on March 31, 2026, the Board of Directors and the Key Managerial Personnel of the Company comprised the following:

As on March 31, 2026, the Board of Directors and the Key Managerial Personnel of the Company comprised the following:

S.N.	Name	Designation	DIN/PAN
1	Sanjaykumar Vitthahlbhai Patel	Managing Director	00370715
2	Pravin Bhadabhai Madhani	Director	00370791
3	Mitesh Lavjibhai Chikhaliya	Director	03342934
4	Tarun Ratilal Dobariya	Independent Director	07554597
5	Keyur Jagdishchandra Shah	Independent Director	03111182
6	Vaishakhi Ambrishbhai Shukla	Independent Director	09738364
7	Nilesh Dharamshibhai Patel	Company Secretary & CFO	--

However, Mr. Nilesh Dharamshibhai Patel was relieved from the position of Company Secretary & CFO of the Company with effect from 31st March, 2026, and Mr. Kunj Anjaykumar Desai was appointed as the Company Secretary & CFO of the Company with effect from 01st April, 2026.

13. DEPOSITS:

The Company has not invited / accepted any deposits from the public during the year under review.

14. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

(A) CONSERVATION OF ENERGY:

Infimum Pharmachem Limited remains committed to achieving operational excellence through continuous improvement in energy efficiency, resource optimization, and sustainable energy management practices across all its operations. The Company is continuously putting its efforts to improve Energy Management by monitoring energy related parameters on a regular basis.

The Company consistently strives to reduce its energy consumption by monitoring key energy parameters, adopting efficient technologies, and implementing continual process improvements across its manufacturing facilities.

(i) The steps taken or impact on conservation of energy;

The Company has set-up a Ground Mounted Solar PV Power Project of 1.1 MW DC (0.900 MW AC). The said project is commissioned in May 2026.

The power generated at the Solar Power Plant will be captively consumed to meet the power requirements of the Existing Plant (Unit-1) as well as Contrast Media Raw Materials Manufacturing Facility (Unit-2) of the company, which will substantially reduce the energy cost.

(ii) The steps taken by the Company for utilizing alternate sources of energy; Following are the steps taken by the Company:

Companys subsidiary Infinium Green Energy Private Limited, has manufactured 4353 metric tons of bio coal from agro waste during this year. Which is a supportive step in the governments determination to double farmers income. And also, the replacement of gas fuel is completely alternative energy regeneration. By using this fuel as a substitute for gas consumption, it has managed to reduce the cost of fuel by almost half. In the coming years, Infinium Green Energy is expecting to increase its production to 6500 metric tons.

(iii) The capital investment on energy conservation equipments: Nil

1. The efforts made towards technology absorption; Nil (ii) The benefits derived like product improvement, cost reduction, product development or import substitution; Nil (iii) In case of imported technology (imported during the last three years reckoned from the beginning of the financial year); Nil (iv) The expenditure incurred on Research and Development; The Companys research and development efforts are focused on technological advancement, process improvement, energy optimization, and the development of sustainable and efficient manufacturing practices.

Foreign Exchange Earnings Foreign Exchange Outgo Foreign Exchange Outgo

15. ANNUAL RETURN:

Pursuant to the provisions of Section 92 of the Companies Act, 2013 read with Rule 12 of the Companies (Management and Administration) Rules, 2014 the Annual Return of the Company shall be placed on the website of the Company. The link for the same is https://infiniupharmachem.com/ .

16. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

During the period under review, there was no contract or arrangements made with the related parties as defined under Section 188 of the Companies Act, 2013. However, the Company has made commercial transactions with its Subsidiaries, on an arms length basis in the ordinary course of its business. Details of the same are mentioned in Annexure C (Form AOC-2) annexed to this report.

17. BUSINESS RISK MANAGEMENT:

In todays economic environment, Risk Management is a very important part of the business. The main aim of risk management is to identify, monitor and take precautionary measures in respect of the events that may pose risks for the business. Your Companys risk management is embedded in the business processes. Your Company has identified certain risks like price risk, uncertain global economic environment, interest rate, human resource, competition, compliance and industrial health and safety risk and also planned to manage such risk by adopting best management practice.

18. CORPORATE SOCIAL RESPONSIBILITY:

The Company remains steadfast in its commitment to social responsibility, consistently directing its resources and initiatives toward causes that foster positive social, ethical, and environmental outcomes. Through a range of Corporate Social Responsibility (CSR) activities, the Company has actively contributed to societal well-being and continues to create enduring value for the community.

In compliance with requirements of Section 135 of the Act, the Company has laid down a CSR Policy. The composition of the Committee, contents of CSR Policy and report on CSR activities carried out during the financial year ended March 31, 2026 in the format prescribed under the Companies (Corporate Social Responsibility Policy) Rules, 2014 is annexed herewith as Annexure D.

19. NUMBER OF MEETINGS OF THE BOARD:

During the year under review, 04 (Four) Board Meetings were held. The maximum gap between any two Board Meetings was less than 120 days.

S.N.	Date of Board Meeting	No. of Directors Present
1.	28.05.2025	06
2.	21.08.2025	06
3.	13.11.2025	06
4.	13.03.2026	06

20. DIRECTORS RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Act, the Board of Directors, to the best of its knowledge and ability, confirm that:

(a) In the preparation of the annual accounts for the Financial Year ended March 31, 2026, the applicable accounting standards had been followed and there are no material departures from the same; (b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company for the Financial Year ended on March 31, 2026 and of the profit and loss of the Company for that period; (c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; (d) The Directors had prepared the annual accounts on a going concern basis; (e) Proper internal financial controls to be followed by the Company has been laid down and that such internal financial controls are adequate and were operating effectively (f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

21. DECLARATION BY INDEPENDENT DIRECTORS:

The Company has received declarations/confirmations from all the Independent Directors of the Company that they meet the criteria of independence as laid down under Section 149(7) of the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Rule 6 of The Companies (Appointment and Qualification of Directors) Rules, 2014.

22. POLICY ON NOMINATION AND REMUNERATION (NRC):

Nomination and Remuneration Policy in the Company is designed to create a high-performance culture. It enables the Company to attract motivated and retained manpower in a competitive market, and to harmonize the aspirations of human resources consistent with the goals of the Company. The Company pays remuneration by way of salary, benefits, perquisites and allowances to its Executive Directors and Key Managerial Personnel. Annual increments are decided by the Nomination and Remuneration Committee within the salary scale approved by the members and are effective from April 1, of each year.

In compliance with the requirements of Section 178 of the Act and Regulation 19 of the SEBI Listing Regulations, 2015, the Company has laid down a Nomination and Remuneration Policy.

The salient features of the NRC Policy are as under:

1. Setting out the objectives of the Policy

2. Definitions for the purposes of the Policy

3. Policy for appointment and removal of Director, KMP and Senior Management

4. Policy relating to the Remuneration for the Managerial Personnel, KMP, Senior Management Personnel & other employees

5. Remuneration to Non-Executive/Independent Director

6. Carry out evaluation of every directors performance and support the board and independent directors in evaluation of the performance of the board, its committees and individual directors

7. Establish a vigil mechanism for directors and employees to report genuine concerns in such manner as may be prescribed;

23. ANNUAL EVALUATION OF PERFORMANCE OF THE BOARD:

Pursuant to the provisions of the Companies Act, 2013, the Board has carried out an annual evaluation of its own performance, the directors individually, as well as the evaluation of the working of its committees. The Company has devised a questionnaire to evaluate the performances of each of Executive and Independent Directors. Such questions are prepared considering the business of the Company and the expectations that the Board have from each of the Directors. The evaluation framework for assessing the performance of Directors comprises of the following key areas:

i. Attendance of Board Meetings and Committee Meetings; ii. Quality of contribution to Board Deliberations; iii. Strategic perspectives or inputs regarding future growth of the Company and its performance; iv. Providing perspectives and feedback going beyond information provided by the management.

24. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186: The Company has given advances to its Subsidiary Company during the period under review and the said advances are within the limits sanctioned/approved by the members of the Company at the Extra-Ordinary General Meeting held on 6th July, 2024.

25. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANYS OPERATIONS IN FUTURE:

No significant and material order has been passed by the Regulators, Courts, Tribunals impacting the going concern status and Companys operations in future.

26. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:

The Companys internal control procedures which include internal financial controls, ensure compliance with various policies, practices and statutes and keeping in view the organizations pace of growth and increasing complexity of operations.

27. MAINTENANCE OF COST RECORDS:

The provisions of Section 148(1) of the Companies Act, 2013 with regard to maintenance of cost records are applicable to the Company and the Company has made and maintained the cost records as specified therein.

The Board of Directors appointed M/s. B R S & Associates, Cost & Management Accountants as Cost Auditors for conducting audit of the cost records maintained by the Company for the Financial Year 2026-27.

28. PARTICULARS OF EMPLOYEE:

None of the employees has received remuneration exceeding the limit stated in Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Disclosure under Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2015 is given in Annexure E.

29. DETAILS OF APPLICATIONS MADE OR PROCEEDING PENDING, IF ANY UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the period under review, no application has been made nor is any application pending by / against the Company under the Insolvency and Bankruptcy Code, 2016.

30. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS:

During the period under review, there was no instance of one-time settlement with any Bank / Financial Institution. Hence, the disclosure relating to the difference between the amount of the valuation done at the time of one-time settlement and the valuation done while taking loan from the Banks / Financial Institutions is not applicable to the Company.

31. COMPLIANCE WITH THE SECRETARIAL STANDARDS:

During the period under review, the Company has complied with Secretarial Standards-1 (SS-1) and Secretarial Standards-2 (SS-2) issued by the Institute of Company Secretaries of India.

32. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has adopted a policy for prevention of sexual harassment at the workplace, in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH Act). An Internal Complaints Committee (ICC) has been duly constituted as per the provisions of the POSH Act to redress complaints regarding sexual harassment at the workplace.

During the financial year under review, the Company has complied with all the provisions of the POSH Act and the rules framed thereunder. Further details are as follow:

Number of complaints of Sexual Harassment received in the Year- NIL Number of Complaints disposed-off during the year- NIL Number of cases pending for more than ninety days- NIL

The Company had also organized POSH Training Session at its factory on 28th February, 2026 where following points were discussed and training was imparted to the employees:

1. Overview of POSH Act and its importance.

2. Roles & Responsibilities of Employees & Employers.

3. Complaint Redressal Mechanism.

4. Case Studies & Group Discussion.

33. AUDIT COMMITTEE: The Committee inter alia reviews the Internal Control System, Reports of Internal Auditors, Key Audit Matters presented by the Statutory Auditors and compliance of various regulations. The Committee also reviews the financial results and financial statements before they are placed before the Board. The audit committee comprises of the following members:

Sr. No.	Name of Committee Members	DIN	Designation in Committee Chairman / Member	Designation in the Company
1	KEYUR JAGDISHCHANDRA SHAH	03111182	Chairman	Independent Director
2	MITESH LAVJIBHAI CHIKHALIYA	03342934	Member	Executive Director
3	TARUN RATILAL DOBARIYA	07554597	Member	Independent Director
4	VAISHAKHI AMBRISHBHAI SHUKLA	09738364	Member	Independent Director

34. CORPORATE GOVERNANCE REPORT:

Since our Company is listed on NSE Emerge (SME Exchange), the provisions of Corporate Governance are not applicable to the Company. A confirmation of Non-Applicability of Report on Corporate Governance is given in Annexure F.

35. LISTING OF SECURITIES:

The equity shares of the Company are listed on NSE emerge platform with security ID/symbol of INFINIUM. The ISIN for equity shares is INEOMRE01011. The Company confirms that the annual listing fees to the stock exchange for the Financial Year 2026-27 have been paid.

36. INTERNAL AUDITORS:

The Board of Directors at their meeting held on August 22, 2026 appointed M/s. Ronak R Jain & Associates, Chartered Accountant as internal auditor for the Financial Year 2026-27.

37. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

The Management Discussion and Analysis Report as required under Regulation 34 read with Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations, 2015) forms part of this report. Certain Statements in the said report may be forward-looking. Many factors may affect the actual results, which could be different from what the Directors envisage in terms of the future performance and outlook. Management Discussion and Analysis Report is given in Annexure - G to the Directors Report.

38. MATERNITY BENEFIT:

The Company affirms that it has duly complied with all provisions of the Maternity Benefit Act, 1961, and has extended all statutory benefits to eligible women employees during the year.

39. CFO CERTIFICATION:

CFO Compliance Certificate as required under Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given in Annexure - H.

40. ACKNOWLEDGMENT:

Your directors would like to express their sincere appreciation for the assistance and cooperation received from the customers, employees, banks, Government authorities, vendors, consultants and members during the year under review.

By Order of the Board of Directors, For, Infinium Pharmachem limited

Sanjaykumar Patel Managing Director DIN:00370715

Place: Anand Date:22nd August,2026

Pravin Madhani Director DIN:00370791